Combination Foretinib and Anti-PD-1 Antibody Immunotherapy for Colorectal Carcinoma
Yuyin Fu,Yujia Peng,Shengyan Zhao,Jun Mou,Lishi Zeng,Xiaohua Jiang,Chengli Yang,Cheng Huang,Yuyan Li,Yin Lu,Mengdan Wu,Yanfang Yang,Ting Kong,Qinhuai Lai,Yangping Wu,Yuqin Yao,Yuxi Wang,Lantu Gou,Jinliang Yang
DOI: https://doi.org/10.3389/fcell.2021.689727
IF: 5.5
2021-07-08
Frontiers in Cell and Developmental Biology
Abstract:Immune checkpoint inhibitors have achieved unprecedented success in cancer immunotherapy. However, the overall response rate to immune checkpoint inhibitor therapy for many cancers is only between 20 and 40%, and even less for colorectal cancer (CRC) patients. Thus, there is an urgent need to develop an efficient immunotherapeutic strategy for CRC. Here, we developed a novel CRC combination therapy consisting of a multiple receptor tyrosine kinase inhibitor (Foretinib) and anti-PD-1 antibody. The combination therapy significantly inhibited tumor growth in mice, led to improved tumor regression without relapse (83% for CT26 tumors and 50% for MC38 tumors) and prolonged overall survival. Mechanistically, Foretinib caused increased levels of PD-L1 via activating the JAK2-STAT1 pathway, which could improve the effectiveness of the immune checkpoint inhibitor. Moreover, the combination therapy remodeled the tumor microenvironment and enhanced anti-tumor immunity by further increasing the infiltration and improving the function of T cells, decreasing the percentage of tumor-associated macrophages (TAMs) and inhibiting their polarization toward the M2 phenotype. Furthermore, the combination therapy inhibited the metastasis of CT26-Luc tumors to the lung in BALB/c mouse by reducing proportions of regulatory T-cells, TAMs and M2 phenotype TAMs in their lungs. This study suggests that a novel combination therapy utilizing both Foretinib and anti-PD-1 antibody could be an effective combination strategy for CRC immunotherapy.
cell biology,developmental biology